TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01749579
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
Study: NCT00161993
Drug: Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01400516
Drug: calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg of calcium citrate
Study: NCT02865915
Drug: MLE4901
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
Study: NCT02865915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match active drug
Study: NCT00357656
Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Normalized name: factor VIII Injection [Recombinate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h.
Study: NCT00357656
Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Normalized name: factor VIII Injection [Recombinate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
Study: NCT00918021
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00615056
Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT00615056
Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT00615056
Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT00615056
Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT03226340
Drug: S-amlodipine 2.5mg + Chlorthalidone 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
Study: NCT02776033
Drug: GSK2982772
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study: NCT03733171
Drug: diluted epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study: NCT00134212
Drug: Dopexamine and norepinephrine
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134212
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02776033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study: NCT02603809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
Study: NCT03662984
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare ciprofibrate
Study: NCT02675335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02759224
Drug: Lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04031833
Drug: MAT2203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encochleated amphotericin B
Study: NCT01145768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01268111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01702740
Drug: 1 mg/kg CNTO 136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT01702740
Drug: 4 mg/kg CNTO 136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT01702740
Drug: 10 mg/kg CNTO 136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT01702740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Study: NCT02419170
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01504321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated lactose powder
Study: NCT00853840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Study: NCT02515942
Drug: CLG561
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515942
Drug: LFG316
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02310919
Drug: Low dose hCG plus FSH co-trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
Study: NCT02310919
Drug: Standard dose of hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of hCG (10,000 or 5,000 IU) trigger
Study: NCT03099148
Drug: LY3337641 (T1)
Normalized name: FORTISCARE T1 (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PO
Study: NCT03099148
Drug: LY3337641 (T2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PO
Study: NCT02365285
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule prior to the infusion of intralipid/heparin
Study: NCT02365285
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
Study: NCT00821249
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study: NCT04348045
Drug: ARM C FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Study: NCT02144155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug
Study: NCT02995044
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
Study: NCT02995044
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT00233623
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00233623
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03127657
Drug: Cock's comb extract 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically twice daily for 12 weeks
Study: NCT04398758
Drug: SanaCutan Basiscreme
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
Study: NCT03222843
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03606681
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
Study: NCT03606681
Drug: TheraCal LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
Study: NCT01727141
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study: NCT01727141
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT01727141
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT01727141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT00448071
Drug: MTR107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03336216
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: specified dose on specified days
Study: NCT03336216
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT01129843
Drug: Directly observed home based daily iron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
Study: NCT03488316
Drug: Manipulation of the temporary filling material based on Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
Study: NCT02477501
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion
Study: NCT03240133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral liquid formulation to match BCX7353
Study: NCT03088553
Drug: Therapeutic Drug Monitoring
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
Study: NCT02262481
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01321788
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Study: NCT01636713
Drug: GSK573719/VI 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study: NCT01636713
Drug: GSK573719/VI 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study: NCT01636713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study: NCT00666757
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-80 mgs orally daily for 12 weeks
Study: NCT02170766
Drug: BIBR 1048 medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02597556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
Study: NCT02273570
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
Study: NCT02273570
Drug: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
Study: NCT00094406
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01231581
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Study: NCT01231581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Study: NCT02646852
Drug: PLX038
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01879228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Study: NCT00473525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD
Study: NCT00473525
Drug: PF-00734200 10 mg QD
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg QD
Study: NCT01313819
Drug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
Study: NCT03335254
Drug: TSX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
Study: NCT00801047
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-50 mic per 1-2 min via PCA
Study: NCT04363450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
Study: NCT03095066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsules
Study: NCT03095066
Drug: AVP-786-42.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study: NCT01649375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00382811
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 8 hours daily in 28 day cycles
Study: NCT01124604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
Study: NCT03751514
Drug: Azithromycin 500 mg
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
Study: NCT02584504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study: NCT02584504
Drug: Non-statin Lipid-Modifying Therapy
Normalized name: LIPID MODIFYING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
Study: NCT03012113
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03667352
Drug: Intravenous Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
Study: NCT02502266
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00539838
Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT00539838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02318290
Drug: Opiates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
Study: NCT01975610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 28 days
Study: NCT01399008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00373945
Drug: Observational Study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01885910
Drug: Doxycycline 100mg
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100mg by mouth once daily
Study: NCT01885910
Drug: Aczone 5% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aczone 5% gel twice daily
Study: NCT01660893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 unilateral intranasal sprays per dose
Study: NCT03532464
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
Study: NCT03532464
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
Study: NCT03090100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
Study: NCT00344383
Drug: Norgestimate/Ethinyl Estradiol tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965443
Drug: Placebo 1 10 mg + Placebo 2 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
Study: NCT03506750
Drug: IVC
Normalized name: DEXTROMETHORPHAN HYDROBROMIDE 10 mg / ACETAMINOPHEN 325 mg / PHENYLEPHRINE HYDROCHLORIDE 5 mg ORAL CAPSULE, LIQUID FILLED [Activcin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
Study: NCT01094496
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no